← All Sponsors

SPONSOR

Dana-Farber Cancer Institute

Total Trials

17

Recruiting

17

Phases

Phase 2, Phase 1, Phase 2, Phase 1

Conditions studied: Pediatric Brain Tumor Prostate Cancer Cardiovascular Diseases Lymphoma Survivorship Multiple Myeloma Carcinoma, Non-Small-Cell Lung Thyroid Cancer Breast Cancer Triple Negative Breast Cancer

High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

Pediatric Brain Tumor

CV CARE: CardioVascular Care in PC Patients

Prostate Cancer

UPLYFT For Lymphoma Survivors

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Multiple Myeloma

NCT03586453 Phase 2

Osimertinib In EGFR Mutant Lung Cancer

Carcinoma, Non-Small-Cell Lung

Hereditary Risk Factors for Thyroid Cancer

NCT04468061 Phase 2

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Urologic Cancer

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

NCT04724018 Phase 1, Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Urothelial Cancer

Geriatric Thoracic Surgery Ambulation Challenge

Thoracic Diseases

NCT04678401 Phase 1

IS-free Treg HaploHCT

Stem Cell Transplant Complications

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

NCT06321484 Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Platinum-resistant Ovarian Cancer

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Genetic Predisposition to Disease

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

NCT03113643 Phase 1

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia